THE EFFECTIVENESS OF PRASTERONE VS PLACEBO THERAPY AS THE VULVOVAGINAL ATROPHY TREATMENT IN MENOPAUSAL WOMEN: META-ANALYSIS STUDY

Authors

  • Zettira Maulida Prasha Fakultas Kedokteran Universitas Airlangga-RSUD Dr. Soetomo Surabaya
  • Hari Paraton

DOI:

https://doi.org/10.33086/mhsj.v4i2.1656

Keywords:

VULVOVAGINAL ATROPHY, MENOPAUSE, PRASTERONE, PLACEBO, SUPERFICIAL CELL, PARABASAL CELL, VAGINAL PH, DISPAREUNIA

Abstract

Background : Vulvovaginal atrophy is a condition that often occurs in menopausal women due to Estrogen decreased. Prasterone (DHEA) is a steroid hormone that can be converted into Estrogen in the target tissue. Objective : This paper aims to evaluate the effectiveness of administering Prasterone as Vulvovaginal Atrophy therapy in menopausal women. Methods : A systematic data search was performed on a medical database (PUBMED, Google scholar, Cochrane). Inclusion criteria: (1) randomized study of Prasterone as Vulvovaginal Atrophy therapy in postmenopausal women, (2) all-inclusive papers can be accessed completely, and (3) the data obtained can be accurately analysed. Results: Three RCTs with a total of 696 patients were analysed. The average number of Superficial Cells (mean difference [MD] 7.63, and 95% [CI] 7.57 to 7.70 (P <0.00001). The average number of Parabasal Cells (mean difference [MD] -29.84, and 95% [CI] -30.25 to -29.44 (P <0.00001). The average number of vaginal pH (mean difference [MD] -0.69, and 95% [CI] -0.70 to -0.68 (P <0.00001). The average number of Dyspareunia (mean difference [MD] -0.38, and 95% [CI] -0.39 to -0.37 (P <0.00001). All diamonds do not intersect the vertical line, and have p <0.05, it proves that there are significant differences between the two groups. All non-hysterectomized women have an atrophic or inactive endometrium. Side effects that are often complained of is headache and application site discharge. Conclusion This meta-analysis concludes that Prasterone therapy has a significant therapeutic effect for Vulvovaginal Atrophy in menopausal women

Downloads

Download data is not yet available.

Author Biography

Hari Paraton

Staff at the Division of Urogynecology and Reconstruction, Department/ Functional Medical Staffs (SMF) of Obstetrics & Gynecology, Faculty of Medicine, Universitas Airlangga– RSUD Dr.Soetomo, Surabaya

References

Labrie F, Martel C, Pelletier G. Is vulvovaginal atrophy due to a lack of both estrogens and androgens? Menopause. 2017;24(4):452–61.

Gandhi J, Chen A, Dagur G, et al. Genitourinary syndrome of menopause: An overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. Am J Obstet Gynecol 2016;215(6):704–11

Labrie F, Belanger A, Pelletier G, et al. Science of intracrinology in postmenopausal women. Menopause. 2017;24(6):702–12.

Archer DF, Labrie F, Montesino M, et al. Comparison of intra- vaginal 6.5 mg (0.50%) prasterone, 0.3 mg conjugated estrogens and 10 μg estradiol on symptoms of vulvovaginal atrophy. J Steroid Biochem Mol Biol. 2017;174:1–8.

European Medicines Agency. Intrarosa: summary of product characteristics. 2019. http://www.ema.europa.eu/. Accessed 20 June 2019.

AMAG Pharmaceuticals. Intrarosa (prasterone insert): US prescribing information. 2018. http://www.fda.gov. Accessed 31 May 2019.

Labrie F, Archer DF, Bouchard C, et al. Intravaginal dehydroepiandros- terone (DHEA, Prasterone), a highly efficient treatment of dyspareunia. Climacteric 2011;14:282-288

Archer DF, Labrie F, Bouchard C, et al. Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepaindrosterone (prasterone). Menopause 2015;22:950-963.

Labrie F, Archer DF, Koltun W, et al. Efficacy of intravaginal dehydroepiandrosterone (DHEA)on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause.

Published

2020-08-28

How to Cite

Prasha, Z. M., & Paraton, H. (2020). THE EFFECTIVENESS OF PRASTERONE VS PLACEBO THERAPY AS THE VULVOVAGINAL ATROPHY TREATMENT IN MENOPAUSAL WOMEN: META-ANALYSIS STUDY. Medical and Health Science Journal, 4(2), 103-108. https://doi.org/10.33086/mhsj.v4i2.1656

Issue

Section

Articles